ClinicalTrials.Veeva

Menu

Efficacy Study of the Effect of Budesonide on Emphysema

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 4

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Drug: Pulmicort (budesonide) Turbuhaler

Study type

Interventional

Funder types

Industry

Identifiers

NCT00232674
AD-004-0001

Details and patient eligibility

About

To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical Chronic Obstructive Pulmonary Disease diagnosis
  • smoker

Exclusion criteria

  • No exacerbation within the last 30 days
  • no long term use of oral corticosteroids

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems